Daiwa Securities Group’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-162
| Closed | -$1K | – | 1382 |
|
|
2025
Q2 | $1K | Hold |
162
| – | – | ﹤0.01% | 1291 |
|
|
2025
Q1 | $1K | Hold |
162
| – | – | ﹤0.01% | 1266 |
|
|
2024
Q4 | $1K | Hold |
162
| – | – | ﹤0.01% | 1276 |
|
|
2024
Q3 | $2K | Hold |
162
| – | – | ﹤0.01% | 1238 |
|
|
2024
Q2 | $2K | Hold |
162
| – | – | ﹤0.01% | 1273 |
|
|
2024
Q1 | $3K | Buy |
+162
| New | +$2.18K | ﹤0.01% | 1251 |
|
|
2022
Q4 | – | Sell |
-149
| Closed | -$2K | – | 1397 |
|
|
2022
Q3 | $2K | Hold |
149
| – | – | ﹤0.01% | 1252 |
|
|
2022
Q2 | $2K | Hold |
149
| – | – | ﹤0.01% | 1260 |
|
|
2022
Q1 | $2K | Hold |
149
| – | – | ﹤0.01% | 1274 |
|
|
2021
Q4 | $2K | Hold |
149
| – | – | ﹤0.01% | 1304 |
|
|
2021
Q3 | $4K | Buy |
149
+73
| +96% | +$2.3K | ﹤0.01% | 1202 |
|
|
2021
Q2 | $3K | Hold |
76
| – | – | ﹤0.01% | 1123 |
|
|
2021
Q1 | $2K | Hold |
76
| – | – | ﹤0.01% | 1166 |
|
|
2020
Q4 | $4K | Sell |
76
-148
| -66% | -$6.85K | ﹤0.01% | 1074 |
|
|
2020
Q3 | $9K | Hold |
224
| – | – | ﹤0.01% | 1051 |
|
|
2020
Q2 | $6K | Hold |
224
| – | – | ﹤0.01% | 1103 |
|
|
2020
Q1 | $6K | Hold |
224
| – | – | ﹤0.01% | 1096 |
|
|
2019
Q4 | $7K | Buy |
+224
| New | +$6.63K | ﹤0.01% | 1090 |
|
Other funds holding YMAB
Daiwa Securities Group's YMAB Position: Q3 2025 in Review
Daiwa Securities Group sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 162 shares — an estimated $1K sold.
Daiwa Securities Group first reported a position in YMAB in Q4 2019 and held it in 18 quarters. The position peaked at $9K in Q3 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Daiwa Securities Group reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Daiwa Securities Group sold 162 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1K.
- Daiwa Securities Group first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 18 quarters.
- Daiwa Securities Group's Y-mAbs Therapeutics position peaked at $9K in Q3 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Daiwa Securities Group's 13F filing for Q3 2025, filed 14 Nov 2025.